Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1991-5-23
|
pubmed:abstractText |
The relationship between the antibody responses to various influenza B type virus HA vaccines and protection against live B virus infection was investigated in Balb/c mice which had been inoculated intranasally with a combination of the HA vaccines and B subunit of cholera toxin (CTB) 4 weeks previously. The inoculation of HA vaccine, prepared from B/Ibaraki/2/85 (B/Ibaraki), B/Nagasaki/1/87 (B/Nagasaki) or B/Aichi/5/88 (B/Aichi) viruses, combined with CTB induced high levels of both nasal IgA and serum HI antibodies to any of B/Ibaraki, B/Nagasaki and B/Aichi viral antigens. Simultaneous inoculation of each CTB-combined HA vaccine provided complete protection against B/Ibaraki virus infection which is demonstrated by both rapid clearance of pulmonary virus and complete survival. On the other hand, the inoculation of HA vaccine prepared from B/Yamagata/16/88 (B/Yamagata) virus together with CTB induced only a low level of nasal IgA antibodies, cross-reactive to B/Ibaraki, B/Nagasaki and B/Aichi viral antigens and protected only partially against B/Ibaraki virus challenge. The involvement of the B type virus-specific immunity in this protection was suggested by the absence of protection against B/Ibaraki virus infection in mice previously inoculated with both A/PR/8/34 (H1N1) virus HA vaccine and CTB. These results suggest that antibodies to various influenza B viruses are cross-reactive to each B type virus antigens and that cross-protection against B virus infection could be conferred depending on the degree of B type virus cross-reactive immunity including secretory IgA antibodies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Cholera Toxin,
http://linkedlifedata.com/resource/pubmed/chemical/Influenza Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/cholera toxin, B subunit (50-64)
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0264-410X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
595-9
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1965078-Animals,
pubmed-meshheading:1965078-Antibodies,
pubmed-meshheading:1965078-Antibody Formation,
pubmed-meshheading:1965078-Antigens, Viral,
pubmed-meshheading:1965078-Cholera Toxin,
pubmed-meshheading:1965078-Cross Reactions,
pubmed-meshheading:1965078-Female,
pubmed-meshheading:1965078-Influenza B virus,
pubmed-meshheading:1965078-Influenza Vaccines,
pubmed-meshheading:1965078-Mice,
pubmed-meshheading:1965078-Mice, Inbred BALB C,
pubmed-meshheading:1965078-Orthomyxoviridae Infections,
pubmed-meshheading:1965078-Peptide Fragments,
pubmed-meshheading:1965078-Vaccination
|
pubmed:year |
1990
|
pubmed:articleTitle |
Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit.
|
pubmed:affiliation |
Department of Pathology, National Institute of Health, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article
|